financetom
Business
financetom
/
Business
/
NVR misses third-quarter profit estimates on higher lot costs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
NVR misses third-quarter profit estimates on higher lot costs
Oct 22, 2024 12:22 PM

Oct 22 (Reuters) - U.S. homebuilder NVR Inc ( NVR )

missed Wall Street estimates for third-quarter earnings per

share on Tuesday as higher lot costs and closing costs

assistance weighed on profit margins.

While demand remains strong, with more skittish buyers

returning to the housing market after some respite in the

popular 30-year fixed mortgage rate, large homebuilders have

kept their prices relatively flat due to still persistent

affordability issues.

Meanwhile land and developed lot costs have seen

inflationary gains, adding more pressure on margins.

NVR's gross profit margins declined to 23.4%, from 24.3%

last year.

Home deliveries in the third quarter ended Sept. 30 rose by

5% to 5,908 units.

Consolidated revenues rose 6% from a year earlier to $2.73

billion, above analysts' estimates of $2.66 billion, according

to data compiled by LSEG.

However, NVR's third-quarter earnings per share of $130.50

came in slightly below analysts' average estimate of $131 per

share, as per data compiled by LSEG, due to higher costs and a

higher effective tax rate.

Shares of the company fell about 2.7% in morning trade.

(Reporting by Ananta Agarwal in Bengaluru; Editing by Mrigank

Dhaniwala)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
Mar 27, 2025
JPMorgan initiated coverage on Ascentage Pharma Group ( AAPG ) , a commercial-stage Chinese biotech company focusing on cancer treatment. In January, Ascentage Pharma’s American depositary shares started trading after the company closed its U.S. initial public offering of 7.325 million ADS at $17.25 per ADS. On Wednesday, JP Morgan said the company’s valuation is largely driven by two late-stage assets...
Update: Sen. Ron Wyden Accuses Pfizer of Tax Dodging After Concluding Investigation
Update: Sen. Ron Wyden Accuses Pfizer of Tax Dodging After Concluding Investigation
Mar 27, 2025
02:52 PM EDT, 03/27/2025 (MT Newswires) -- (Update with Pfizer's ( PFE ) response to a request for comment.) Pfizer ( PFE ) sold $20 billion of drugs to US patients in 2019, but reported zero taxable profits by claiming that 100% of the profits were earned offshore, according to the findings of an investigation conducted by Senate Finance Committee...
US beef sales to China skid after Beijing lets export registrations lapse
US beef sales to China skid after Beijing lets export registrations lapse
Mar 27, 2025
CHICAGO, March 27 (Reuters) - U.S. beef sales to China have taken a dive, U.S. government data showed on Thursday, after Beijing allowed the expiration of registrations that had permitted exports from hundreds of American meat facilities. A tit-for-tat tariff dispute has also raised duties on U.S. meat and other goods shipped to China, making the products less attractive to...
Tesla, Rivian Likely to Fare Better Amid US Tariffs, UBS Says
Tesla, Rivian Likely to Fare Better Amid US Tariffs, UBS Says
Mar 27, 2025
03:08 PM EDT, 03/27/2025 (MT Newswires) -- Tesla (TSLA) and Rivian Automotive ( RIVN ) are likely to fare better after President Donald Trump signed an executive order placing a 25% tariff on automobiles and parts imported to the US, UBS said in a Thursday report. We believe TSLA and RIVN could fare better as 100% of their production is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved